News & Updates
Filter by Specialty:

Triplet therapy with ARSI, docetaxel, ADT boosts survival in mHSPC
05 Sep 2022
byTristan Manalac
Adding androgen receptor signaling inhibitors (ARSI) to a treatment regimen consisting of docetaxel and androgen deprivation therapy (ADT) can lead to better survival outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to a recent meta-analysis.